Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER by unknown
NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - ORIGINAL ARTICLE
Rotigotine transdermal system for long-term treatment of patients
with advanced Parkinson’s disease: results of two open-label
extension studies, CLEOPATRA-PD and PREFER
Peter A. LeWitt • Babak Boroojerdi •
Erwin Surmann • Werner Poewe
Received: 13 February 2012 / Accepted: 16 November 2012 / Published online: 4 December 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Open-label extensions [studies SP516 (NCT00
501969) and SP715 (NCT00594386)] of the CLEO-
PATRA-PD and PREFER studies were conducted to
evaluate the safety, tolerability and efficacy of the dopa-
minergic agonist, rotigotine, over several years of follow-
up in patients with advanced Parkinson’s disease (PD).
Eligible subjects completing the double-blind trials
received open-label adjunctive rotigotine (B16 mg/24 h)
for up to 4 and 6 years in Studies SP516 and SP715,
respectively. Safety and tolerability were assessed using
adverse events, vital signs and laboratory parameters, and
efficacy assessed using the unified Parkinson’s disease
rating scale (UPDRS). Of the 395 and 258 patients enrolled
in the SP516 and SP715 studies, 48 and 45 % completed,
respectively. Adverse events were typically dopaminergic
effects [e.g., somnolence (18–25 %/patient-year), insomnia
(5–7 %/patient-year), dyskinesias (4–8 %/patient-year) and
hallucinations (4–8 %/patient-year)], or related to the
transdermal application of a patch (application site reac-
tions: 14–15 %/patient-year). There were no clinically
relevant changes in vital signs or laboratory parameters in
either study. Mean UPDRS part II (activities of daily liv-
ing) and part III (motor function) total scores improved
from double-blind baseline during dose titration, then
gradually declined over the maintenance period. In study
SP516, mean UPDRS part II and III total scores were 0.8
points above and 2.8 points below double-blind baseline,
respectively, at end of treatment. In study SP715, mean
UPDRS part II and III total scores were 4.1 points above
and 0.2 points below baseline, respectively, at end of
treatment. In these open-label studies, adjunctive rotigotine
was efficacious with an acceptable safety and tolerability
profile in patients with advanced PD for up to 6 years.
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Introduction
Levodopa (L-dopa), an amino acid precursor of dopamine,
has been the mainstay of therapy for Parkinson’s disease
(PD) for more than 40 years (LeWitt 2008). However,
long-term treatment with L-dopa is often associated with
the development of motor response fluctuations and
dyskinesias (Nutt 2001). These problems are intrinsic to
L-dopa therapy and are possibly the result of the pulsatile
dopaminergic agonist receptor stimulation that is associ-
ated with the short peripheral clearance half-life of L-dopa
(Olanow et al. 2006; Antonini et al. 2009). Research for
new PD therapies has focused on developing drugs with
extended dopaminergic stimulation, particularly dopami-
nergic agonists (LeWitt 2010). The latest dopaminergic
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agonist to be marketed is rotigotine, a non-ergolinic
dopamine receptor agonist with activity across D1 through
D5 receptors, as well as at selected adrenergic and sero-
tonergic sites. Rotigotine is administered via a transdermal
delivery system left in place for 24 h. This enables con-
tinuous drug delivery and, therefore, stable plasma drug
concentrations over the 24-h period (Jenner 2005; Rascol
and Perez-Lloret 2009; Boroojerdi et al. 2010). Rotigotine
transdermal system is licensed by the US Food and Drug
Administration for the treatment of the signs and symptoms
of early-stage idiopathic PD, and is approved for the
treatment of early- and advanced-stage idiopathic PD, and
for moderate-to-severe idiopathic restless legs syndrome in
adults in the European Union.
In several short-term, randomized, double-blind clinical
studies, rotigotine has demonstrated statistically significant
treatment benefits and good tolerability in both early- and
advanced-stage PD (Parkinson Study Group 2003; Giladi
et al. 2007; Jankovic et al. 2007; Watts et al. 2007). Like
other dopaminergic agonists, it can be used as a substitute
for the previous dose of L-dopa needed by patients with
either early- or advanced PD (Pham and Nogid 2008).
In the RECOVER (randomized evaluation of the 24-h
coverage: efficacy of rotigotine) study, rotigotine, added to
L-dopa, was associated with significant improvements in
early-morning motor function and nocturnal sleep distur-
bances in patients with early-morning motor dysfunction
(Trenkwalder et al. 2011). Other clinical outcomes with
rotigotine have included improvement in overall perfor-
mance in activities of daily living (ADLs) and a reduction
in the proportion of L-dopa-treated patients awakening in
an ‘‘OFF’’ state (Pahwa et al. 2009). In addition, adjunctive
rotigotine resulted in significant reductions in ‘‘OFF’’ time
and was generally well tolerated in L-dopa-treated patients
with advanced PD with motor fluctuations in two multi-
center, 6-month, randomized, double-blind, placebo-
controlled trials—CLEOPATRA-PD (clinical efficacy of
Pramipexole and transdermal rotigotine in advanced PD)
(Poewe et al. 2007) and PREFER (prospective randomized
evaluation of a new formulation: efficacy of rotigotine)
(LeWitt et al. 2007).
As PD progresses, patients tend to have increased
symptomatology and disability. Furthermore, patients with
advanced PD require increasing doses of L-dopa, resulting
in more frequent drug-induced problems such as dyskine-
sias and motor fluctuations. Only a few open-label studies
have been conducted that evaluate the long-term safety and
efficacy of the available non-ergot dopaminergic agonists
in patients with PD (Rascol et al. 2000; Holloway
et al. 2004; Hauser et al. 2007; Parkinson Study Group
CALM Cohort Investigators 2009). Here, we report the
results of open-label extensions of the CLEOPATRA-PD
(study SP516; clinicaltrials.gov identifier: NCT00501969)
and PREFER (SP715; clinicaltrials.gov identifier: NCT005
94386) studies, conducted to evaluate the long-term safety,
tolerability and efficacy of adjunctive transdermal rotigo-
tine in patients with advanced PD.
Materials and methods
Patients
Eligibility criteria for the PREFER and CLEOPATRA-PD
double-blind studies have been reported previously (Poewe
et al. 2007; LeWitt et al. 2007). These were, in brief, a
diagnosis of idiopathic PD for at least 3 years, an average
of 2.5 h of ‘‘OFF’’ time on the 24-h self-report motor
function diaries, and Hoehn and Yahr stage II to IV in both
‘‘ON’’ and ‘‘OFF’’ states. In addition, patients had to be
receiving stable doses of L-dopa of C200 mg/day in at least
twice daily doses for entry to PREFER and C300 mg/day
in at least three daily doses for entry to CLEOPATRA-PD,
with no change in any concomitant anti-PD medication for
at least 28 days prior to baseline. Patients were excluded
from the double-blind studies if they had received therapy
with a dopaminergic agonist, methylphenidate, amphet-
amine, entacapone or tolcapone within 28 days of baseline.
Patients who completed the double-blind dose mainte-
nance period of their study were eligible for entry into the
respective open-label extension, provided there were no
ongoing serious adverse events (AEs) related to trial med-
ication. Those receiving approved concomitant PD medi-
cations were required to be on a stable dose which remained
unchanged until the dose titration period with rotigotine was
complete and the optimal dose of rotigotine had been con-
firmed [after 1 month of maintenance (see below)]. In
addition, investigators were encouraged not to increase the
doses of other PD medications or to initiate other adjunctive
PD therapy during the maintenance period until the rotig-
otine dose was at its maximum of 16 mg/24 h. During the
open-label studies, use of L-dopa (in combination with
benserazide or carbidopa) was continued and the following
medications were also permitted: selegiline, rasagiline, anti-
cholinergic drugs, entacapone, tolcapone, certain atypical
neuroleptics (olanzapine, ziprasidone, aripiprazole, cloza-
pine, quetiapine) and modafinil. Anti-emetic drugs were
also permitted to treat nausea and vomiting caused by
excess dopaminergic stimulation.
Study design
At the end of the double-blind studies, rotigotine-treated
patients who decided to participate in the extensions had
their dose of rotigotine de-escalated in a blinded fashion to
4 mg/24 h over either a 6-day period (study SP516; the
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CLEOPATRA-PD extension study) or an 8-day period
(study SP715; the PREFER extension study) (Fig. 1).
Patients who completed the double-blind studies on a dose
of 4 mg/24 h did not require dose de-escalation and
patients who had been randomized to placebo continued to
receive placebo during de-escalation. Dose de-escalation
was followed by up-titration in 2 mg/24 h increments
every 7 (±3) days to the subject’s optimal dose (up to a
maximum of 16 mg/24 h in both studies except for the first
year of study SP715 when the maximum dose was 12 mg/
24 h). The titration periods lasted up to 7 weeks. If AEs
thought to be related to excessive dopaminergic stimulation
occurred during the titration period, reduction of the rot-
igotine dose was permitted once during this period. Once
the titration period was complete, or the optimal dose had
been reached, the maintenance period began. Rotigotine
dose could be increased or decreased as needed during the
maintenance period to maintain an effective dose for each
patient. End of rotigotine treatment could have occurred at
any time during the trials. At the time of study closure,
which was after up to 4 years in study SP516 and up to
6 years in study SP715, an end of treatment (EoT) visit
took place, at which patients began dose de-escalation in
2 mg/24 h steps every 2 days over a period of up to
12 days. The end of treatment visit was also conducted for
patients who withdrew prematurely, provided that the
assessments could be performed within 24 h of the final
patch administration. A safety follow-up visit was con-
ducted within 28 days of the final patch application. Clinic
visits occurred at the start of the maintenance period, 1 and
3 months later, and then at 3-month intervals until the end
of the maintenance period.
Outcome measures
The primary variables were AEs, as reported spontaneously
by the patient or observed by the investigator; and change
from baseline in vital signs, body weight, electrocardio-
gram, clinical laboratory values, Epworth sleepiness scale
(ESS) scores, and physical and neurological examinations
over the course of the study.
Efficacy outcome measures in both studies were the
unified Parkinson’s disease rating scale (UPDRS) part II
(ADLs) and part III (motor examination), and Hoehn and
Yahr assessments (to assess the severity and progression of
disease). UPDRS part IV (complications of therapy) was
used for the assessment of the incidence of dyskinesias
(‘‘What proportion of the waking day are dyskinesias
present?’’) and the duration of ‘‘OFF’’ time (‘‘What pro-
portion of the waking day is the patient ‘‘OFF’’ on
average?’’).
UPDRS parts II and III, and Hoehn and Yahr staging
were completed while the patient was in an ‘‘ON’’ state.
All UPDRS assessments were performed, and the investi-
gator’s clinical global impression (CGI) of the patient’s
symptoms recorded, at every clinic visit. Hoehn and Yahr
staging was recorded in the ‘‘ON’’ state at visits 11 and 13
of study SP516, and visit 9 of study SP715; then repeated
Fig. 1 Design of open-label extension studies for participants from the CLEOPATRA-PD and PREFER studies
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every 6 months throughout the treatment period and at the
EoT visit for both studies. Changes in adjunctive L-dopa
therapy were monitored throughout both studies.
Data analysis
Safety and efficacy analyses were performed on the safety
set—defined as all subjects who received at least one dose
of rotigotine in the open-label extension—and are reported
as observed cases. In addition, the UPDRS part IV item
‘‘What proportion of the waking day is the patient ‘OFF’
on average?’’ was analyzed based on last observation car-
ried forward values. The primary safety variables were
analyzed descriptively. AEs were evaluated according to
their seriousness, intensity, outcome and causality. A
serious AE was one which, at any dose, was fatal and life-
threatening, resulted in persistent or significant disability or
incapacity, resulted in hospitalization or the prolongation
of existing hospitalization, or was considered to be an
important medical event. The intensity of each AE was
classified as mild (did not interfere with routine activities),
moderate (interfered with routine activities) or severe
(subject was unable to perform routine activities). The
outcome of each AE was described as fatal, ongoing,
recovering, recovering with sequelae, recovered or lost to
follow-up. The causality of each AE was related to the
likelihood of a relationship with the study drug and ranged
from ‘‘not related’’ to ‘‘highly probable’’. An exposure-
adjusted incidence of AEs was calculated by taking the
total number of events reported (both unique and non-
unique) and dividing it by the sum, over all patients
reporting that particular AE, of the treatment period in
years, yielding an AE incidence per patient-year.
Endpoints were changed from baseline to EoT in each
outcome measure where baseline was visit 2 of the relevant
double-blind trial except for Hoehn and Yahr, where
baseline was visit 1 of the double-blind study, and the
UPDRS part IV item ‘‘What proportion of the waking day
are dyskinesias present?’’ in study SP715 where baseline
was visit 1 of the open-label study.
Descriptive statistics were provided for measured values
and changes from baseline by visit for the UPDRS parts II
and III. A responder analysis for UPDRS parts II and III
was performed, where a responder was defined as a subject
who had improved by C20 % in the UPDRS parts II and III
sum score compared with baseline.
Results
Patient disposition and treatment
Of the 506 patients randomized in the CLEOPATRA-PD
study, 428 (85 %) completed and were eligible to enroll in
the open-label extension (study SP516; Fig. 1) (Poewe et al.
2007). Of these, 395 did so, with 189 (48 %) still partici-
pating in the study at study closure. Of the 351 patients
randomized in the PREFER study, 260 (74 %) completed,
with 259 eligible to enroll in the open-label extension (study
SP715; Fig. 1; LeWitt et al. 2007). All but one patient did
so, with 115 (45 %) still participating at study end.
Demographic and clinical characteristics at double-blind
baseline were similar for subjects in both open-label
extension studies (Table 1), with the majority of subjects
(55 % in study SP516 and 59 % in study SP715) having a
CGI of four at baseline, indicative of moderately severe PD.
In study SP516, the most common rotigotine dose on
entering the open-label maintenance phase was the 16 mg/
24 h dose (41 % of patients) while for study SP715, it was
the 12 mg/24 h dose (54 % of patients). The rotigotine
dose remained relatively stable over the maintenance
periods of both studies (see annotated doses on Figs. 2, 3)
with a slightly higher mean dose at EoT in study SP516
(11.6 ± 3.2 mg/24 h) compared with study SP715 (10.1 ±
3.4 mg/24 h). Mean exposure to rotigotine in studies
SP516 and SP715 (double-blind and open-label phases
combined) was 1,017.9 (±458.1) days and 1,538.8 (±609.3)
days, respectively. L-Dopa was taken concomitantly by all
subjects during the treatment periods of both studies and its
mean daily dose increased over time in both (see annotated
doses on Figs. 2, 3).
Other anti-PD drugs taken during the treatment period
included selegiline and rasagiline (18 % of patients in
study SP516 and 28 % in study SP715), amantadine (26 %











Age in years, mean ± SD (range) 64.4 ± 9.2 (39–84) 66.4 ± 9.6 (34–88)
Male, N (%) 251 (64) 173 (67)
Caucasian, N (%) 385 (97) 240 (93)
Time since first diagnosis in years, mean ± SD (range) 8.5 ± 4.6 (3–29) 7. 8 ± 4.5 (2–24)
UPDRS part II score in years, mean ± SD (range) 12.3 ± 5.9 (0–33) 12.6 ± 6.4 (0–36)
UPDRS part III score in yeras, mean ± SD (range) 27.0 ± 11.7 (1–65) 26.1 ± 13.8 (0–83)
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of patients in study SP516 and 27 % in study SP715) and
other dopamine agonists (9 % in study SP516 and 15 % in
study SP715). Anti-emetics and anti-nauseants were taken
by 11 patients (3 %) during the treatment period of study
SP516 and by 28 patients (11 %) during the treatment
period of study SP715.
Safety and tolerability
In study SP516, 90 % of patients reported at least one AE
and the figure was 100 % in study SP715. For both studies,
the absolute and exposure-adjusted incidence of those AEs
reported with an incidence C5 % per patient-year during
open-label treatment is shown in Table 2. Data on AE
severity and its link to study discontinuation are also
shown. Most AEs were mild or moderate in intensity; only
8 and 9 % of all AEs reported in studies SP516 and SP715,
respectively, were recorded as severe and few resulted in
study discontinuation. In addition, most AEs (63 % in
study SP516 and 62 % in study SP715) had resolved at the
end of trial participation.
Overall, serious AEs occurred across system organ
classes in both studies with no obvious grouping or trend.
During study SP516, 148 patients (37 %) reported a total of
273 serious AEs which included 17 that were associated
with the death of 15 patients (4 %), while in study SP715,
165 patients (64 %) reported a total of 437 serious AEs
including 29 that led to the death of 28 patients (11 %). All
the serious AEs which led to death were judged by the
investigators to be unrelated to, or unlikely to be related to,
study medication except for one case of myocardial
infarction in study SP516 and one case each of circulatory
collapse and urosepsis in study SP715 which were judged
to be possibly related to rotigotine.
The same three AEs—somnolence, fall and application
site reactions (ASRs)—were the most frequently reported
AEs in both studies (Table 2), although there were some
variations between the studies in the incidence of other
common AEs. For AEs in general, most occurrences of
somnolence, fall and ASRs were mild or moderate in
intensity although 17 % of falls in study SP516 were
recorded as severe (Table 2). Four falls by four patients
(1 %) in this study were considered to be serious, while in
study SP715 14 falls by 13 patients (5 %) were considered
to be serious. There were no serious cases of somnolence in
either study. ASRs occurred with relatively high frequency
Fig. 2 Change from baseline
(visit two of double-blind study)
in UPDRS part II (ADL) and
part III (motor function) scores
during open-label treatment in
study SP516; safety set,
observed cases. Mean rotigotine
and L-dopa doses shown by
timepoint. ADL activities of
daily living, BL double-blind
baseline, EoT end of treatment,
L-dopa levodopa, SD standard
deviation, UPDRS united
Parkinson’s disease rating scale.
Patients were followed for up to
4 years; data are not shown
beyond 3.5 years due to \50
patients with measurements at
these timepoints
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in both studies (Table 2) and of all AEs led to the greatest
number of discontinuations [by 14 subjects (3.5 %)] in
study SP516 (Table 2). In study SP516, the mean time
from start of treatment to the first onset of an ASR was 110
(±158) days; two were serious, seven severe and 72 % had
resolved by study completion. In study SP715, the mean
time from start of treatment to the first onset of an ASR was
228 (±370) days; none was severe or serious; and 83 %
had resolved by study completion. Analysis of the expo-
sure-adjusted incidence (percentage per patient-year) of
AEs by rotigotine dose at AE onset (Table 3) revealed that,
in both studies, there was a trend toward a decreased
exposure-adjusted incidence of ASRs with increasing rot-
igotine dose. This was true also of nausea (Table 3) though
no particular trend could be identified for other common
AEs. Absolute incidence of nausea was highest in the first
year of open-label treatment than in all subsequent study
years: in study SP516, nausea was reported by 46 patients
(12 %) in year 1, five patients (2 %) in year 2, four patients
(2 %) in year 3, and zero in year 4. In study SP715, nausea
was reported by 44 patients (17 %) in year 1, nine patients
(4 %) in each of years 2 and 3, two patients (1 %) in year 4,
four patients (3 %) in year 5, and two patients (3 %) in
year 6.
In study SP516, 25 AEs in 23 patients who discontinued
(nine of ASRs, four of hallucination, and one each of
confusional state, delirium, pathological gambling, sleep
attacks, nausea, PD, vomiting, rash with pruritis, contact
dermatitis, severe skin reaction, emotional distress and
erythema) were considered to be very probably related to
study medication. In study SP715, only three of the AEs
that led to discontinuation (hallucination, dementia and
itching at application site) were considered to be very
probably related to study medication.
Hallucinations and compulsive behaviors are typical
side-effects of dopaminergic agonists. Indeed, hallucina-
tion led to the greatest number of discontinuations [six
subjects (2 %); Table 2] in study SP715. All but seven of
the 76 cases of hallucination in this study (Table 2) were
mild or moderate in intensity and eight cases in eight
patients (3 %) were considered to be serious. Of the 39
reported cases of hallucination in study SP516 (Table 2),
all but four were mild or moderate in intensity and four
cases in four patients (1 %) were considered to be serious.
Of 42 AEs indicative of impulsive-compulsive behavior
reported by 22 patients (6 %) in study SP516, 25 [in
16 subjects (4 %)] were assessed by the investigators as
being probably or highly probably related to the trial
medication. Two patients (0.5 %) discontinued the study as
a result of these behaviors and four others (1 %) had their
dose reduced; in all four, the AE was resolved at the end of
the study. In study SP715, a total of 28 AEs indicative of
Fig. 3 Change from baseline
(visit two of double-blind study)
UPDRS part II (ADL) and part
III (motor function) scores
during open-label treatment in
SP715; safety set, observed
cases. Mean rotigotine and
L-dopa doses shown by
timepoint. ADL activities of
daily living, BL double-blind
baseline, EoT end of treatment,
L-dopa levodopa, SD standard
deviation, UPDRS united
Parkinson’s disease rating scale.
Patients were followed for up to
4 years; data are not shown
beyond 3.5 years due to \50
patients with measurements at
these timepoints
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impulsive-compulsive behavior were reported by 21
patients (8 %). Of these, 15 [in 10 subjects (4 %)] were
assessed as being probably or highly probably related to the
trial medication. Three patients (1 %) discontinued as a
result of these AEs and four others (2 %) had their dose
reduced; in all but one of these four patients, the AE was
resolved at the end of the study. With the exception of one
case of worsening of a gambling addiction, one case of
pathological gambling and one case of obsessive compul-
sive symptoms in study SP516, and two cases of compul-
sive gambling in study SP715, all the AEs indicative of
impulsive-compulsive behavior were judged to be not
serious and almost all were mild or moderate in intensity.
In addition, there was no notable variation in the incidence
of psychiatric AEs, including hallucination, insomnia,
confusional state, depression, anxiety, abnormal dreams
and nightmare, by year of open-label treatment in either
study.
The majority of patients (69 % in study SP516 and 80 %
in study SP715) developed dyskinesias during the open-
label extension studies (according to AE reporting or UP-
DRS part IV item ‘‘What proportion of the waking day are
dyskinesias present?’’). Across both studies, dyskinesias
occurred with an incidence of 4–8 % per patient-year.
The mean ESS score increased from 7.1 (±4.5) at
double-blind baseline to 8.4 (±5.2) at EoT in study SP516
and from 7.8 (±4.3) at double-blind baseline to 10.0 (±5.4)
at EoT in study SP715. Except for some minor changes in
hematocrit, hemoglobin and red blood cell count in study
SP715, there were no clinically relevant changes in vital
signs or laboratory parameters in either study.
Efficacy
At double-blind baseline, 59 and 66 % of patients in
studies SP516 and SP715 were Hoehn and Yahr stage II,
respectively. By EoT, these proportions had decreased to
37 and 35 %, respectively. Concomitantly, 2 and 3 % of
patients in studies SP516 and SP715 were Hoehn and Yahr
stage IV, respectively, at baseline, increasing to 10 and
20 % at EoT. These data demonstrate continuing disease
progression over the course of both studies.
Over the open-label titration periods of studies SP516
and SP715, the mean UPDRS part II score (ADLs)
improved relative to double-blind baseline by 4.5 and 4.9
points, respectively (Figs. 2, 3). Scores then gradually
increased (indicative of deterioration in ADLs) over the
maintenance periods of both studies. By EoT of study
SP516, the mean UPDRS part II score was still close to its
baseline value (?0.8 points; Fig. 2), while in study SP715
it was 4.1 points higher (Fig. 3).
In study SP516, mean UPDRS part III scores (motor
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points during titration, then gradually declined, but were
still improved relative to baseline by 2.8 points at EoT
(Fig. 2). In study SP715, they declined from an initial 11.4-
point improvement at the end of the titration period to
baseline values (-0.2 points) at EoT (Fig. 3).
At the end of the titration periods of studies SP516 and
SP715, 71 and 74 % of all patients were classified as
responders on the UPDRS parts II and III sum score,
respectively. Consistent with the individual UPDRS parts
II and III scores, responder rates in both studies decreased
over time but, at EoT, 36 % of patients in study SP516 and
24 % of patients in study SP715 were still classified as
responders.
At the first visit of the maintenance periods of studies
SP516 and SP715, UPDRS part IV item ‘‘What proportion
of the waking day is the subject ‘OFF’ on average?’’ was
improved relative to baseline (Visit 2 of the double-blind
study) by 0.8 and 0.9 points, respectively. This improve-
ment was maintained with little variation over the course of
the maintenance periods, declining slightly to 0.4 point at
EoT of study SP516 and 0.5 point at EoT of study SP715.
In study SP516, a total of ten patients (3 %) spent none of
their waking day in the ‘‘OFF’’ state at baseline (Visit 2 of
the double-blind study), while at EoT this had increased to
34 patients (10 %). In study SP715, a total of 12 patients
(5 %) spent none of their waking day in the ‘‘OFF’’ state at
baseline (Visit 1 of the open-label study), while at EoT this
had increased to 32 patients (12 %).
According to the mean CGI score, which was unchanged
from its double-blind baseline value of 4.1 at the end of
open-label treatment in SP516, there was no change in the
severity of patients’ PD after 4 years of open-label rotig-
otine treatment. In SP715, there was a slight increase in
disease severity over the 6 years of the study, as shown by
an increase in mean CGI score from 3.9 at double-blind
baseline to 4.1 at the end of open-label treatment.
Discussion
In the open-label follow-up of the CLEOPATRA-PD study,
48 % of patients completed 4 years of treatment while
20 % withdrew due to AEs. In the open-label follow-up of
the PREFER study, 45 % of patients completed 6 years of
treatment while 28 % withdrew due to AEs. Rotigotine was
well tolerated in both studies and AEs were generally mild
or moderate in intensity. The two studies had similar AE
profiles, with mainly typical dopaminergic effects such as
Table 3 Exposure-adjusted incidence (percentage per patient-year) of selected AEs (typical dopaminergic AEs and ASRs) by rotigotine dose at


















Somnolence SP516 18.8 11.4 32.7 11.5 16.9 20.3 17.4
SP715 30.7 19.6 33.4 27.7 27.2 23.5 16.7
Fall SP516 37.6 28.5 14.0 22.0 16.1 8.6 8.7
SP715 30.7 21.0 40.8 24.3 24.4 8.8 18.5
ASRc SP516 145.9 31.3 23.3 16.8 8.8 6.2 9.4
SP715 86.9 21.0 23.2 11.7 17.3 1.8 4.2
Peripheral
edema
SP516 4.7 8.5 1.2 2.1 7.2 3.1 3.2
SP715 15.3 14.0 19.5 13.4 10.2 10.6 7.8
Nausea SP516 61.2 17.1 21.0 8.4 4.0 3.1 1.8
SP715 122.6 14.0 15.8 10.9 4.2 2.9 4.8
Dyskinesia SP516 32.9 31.3 15.2 7.3 6.4 7.0 4.8
SP715 10.2 5.6 5.6 6.7 2.5 2.9 1.2
Hallucination SP516 4.7 5.7 2.3 6.3 2.4 7.0 3.7
SP715 10.2 9.8 7.4 11.7 9.2 5.3 6.0
Insomnia SP516 18.8 14.2 7.0 4.2 6.4 7.0 3.4
SP715 15.3 1.4 11.1 7.5 7.4 4.7 7.2
AE adverse event, ASR application site reaction, PM sum of patient months
a PM value of SP715 study
b PM value of SP516 study
c MedDRA high-level term, application and instillation site reactions
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somnolence, insomnia, dyskinesias, hallucinations and
nausea. Indeed, together with fall and ASRs, somnolence
was one of the most frequently reported AEs in both
studies, but almost all cases were mild in intensity and
none were serious. With the exception of ASRs, a known
side-effect of the rotigotine patch, the AE profiles were
similar to those observed in previous long-term studies of
other dopaminergic agonists (Rascol et al. 2000; Holloway
et al. 2004; Mo¨ller et al. 2005; Parkinson Study Group
CALM Cohort Investigators 2009). Compulsive behaviors
are known to be a typical side-effect of dopaminergic
agonists but their overall incidence in these studies was low
(6 % in study SP516 and 8 % in study SP715). Moreover,
except for one case of worsening of a gambling addiction,
one case of pathological gambling and one case of obses-
sive compulsive symptoms in study SP516, and two cases
of compulsive gambling in study SP715, none of the AEs
indicative of impulsive-compulsive behavior were serious.
In addition, they were almost all mild or moderate in
intensity.
The spectrum of AEs reported in the open-label exten-
sions was similar to those in the preceding double-blind
studies. However, some AEs occurred with higher fre-
quency in the open-label study compared with the double-
blind study. For example, of those AEs in study SP715
judged by the investigator as being possibly related to the
study drug, fall and contusion were among the most com-
mon AEs in the open-label extension but not in the pre-
ceding double-blind study. In study SP516, insomnia, one
of the AEs judged to be possibly related to the study drug,
occurred with higher incidence in the open-label study
compared with the double-blind one. It is not clear whether
this indicates that some AEs occur only with prolonged use
of rotigotine, or whether this is simply the consequence of
patients’ comorbidities and age, the addition of other
medications and natural disease progression over the long
period of follow-up. There were also AEs that occurred less
frequently in the open-label compared with the double-
blind studies. For example, the incidence of nausea was 7
and 10 % per patient-year in studies SP516 and SP715,
respectively, compared with an absolute incidence of 17 %
in CLEOPATRA-PD and 24–28 % in PREFER. In addi-
tion, the absolute incidence of nausea was highest in the
first year of open-label treatment than in all subsequent
study years and its exposure-adjusted incidence was higher
at lower doses of rotigotine. As these lower doses tended to
be the transient titration doses, this could suggest that
nausea resolves with continued use of rotigotine. It cannot
be excluded that the use of anti-emetics may have con-
tributed some part to this reduction over time. However, in
study SP516, only 11 patients took anti-emetics, so it is
unlikely that this was responsible for the decrease in the
incidence over time. In study SP715, 28 patients took anti-
emetics, but the exact contribution to reduction in nausea
cannot be accurately assessed as it is not known how many
patients who experienced nausea in year one subsequently
discontinued for this or other reasons. These observations
may also be the result of the selective drop-out of patients
with nausea or the failure to enroll patients with nausea into
the open-label studies. However, only two rotigotine-trea-
ted patients (1 %) discontinued CLEOPATRA-PD and
eight rotigotine-treated patients (3 %) discontinued PRE-
FER due to nausea. In addition, 92 and 99 % of those who
completed the CLEOPATRA-PD and PREFER studies,
respectively, entered the open-label extensions. Overall
5 % of subjects randomized to rotigotine in CLEOPATRA-
PD withdrew due to AEs and 1 % due to inefficacy, while
in PREFER, 17 % of those randomized to rotigotine
withdrew (or were excluded from the intent-to treat pop-
ulation) due to AEs and 5 % due to inefficacy. Hence, it is
doubtful that the patient composition of the open-label
extension studies has been biased by any pre-selection on
the basis of response to rotigotine in the preceding double-
blind studies.
ASRs are associated with the rotigotine transdermal
system, and occurred with an absolute incidence of 26 % in
study SP516 and 33 % in study SP715, compared with
approximately 18 % in CLEOPATRA-PD (Poewe et al.
2007) and 36 or 46 % depending on rotigotine dose in
PREFER (LeWitt et al. 2007). Most ASRs in the open-
label studies were also reported at the lower doses of rot-
igotine as seen for nausea. With discontinuation rates due
to ASRs of 3 and 2 % among the rotigotine-treated patients
in CLEOPATRA-PD and PREFER, respectively, again this
indicates that there has been no pre-selection of patients not
suffering from ASRs. These results suggest that ASRs, like
nausea, may resolve with continued use. The observed
ASRs did not appear to present any long-term safety or
tolerability issues as they were mostly mild; none were
serious and they were associated with only a few discon-
tinuations. Only 14 patients (4 %) discontinued prema-
turely due to ASRs in SP516, while this was the case for
only one patient (0.4 %) in study SP715. Overall rates of
discontinuation due to AEs in these studies (20 and 28 %
of subjects in studies SP516 and SP715, respectively) were
similar to those in long-term studies with the oral dopa-
minergic agonists, pramipexole and ropinirole, in both
early and advanced PD (Rascol et al. 2000; Holloway et al.
2004; Hauser et al. 2007; Parkinson Study Group CALM
Cohort Investigators 2009). Since ASRs are not a factor for
oral drugs, the comparable rate of drug discontinuation in
all of the studies suggests that there are no major tolera-
bility issues specifically associated with the use of the
transdermal patch.
The occurrence of dyskinesias is of interest in long-term
studies such as those described here. Even though
Rotigotine transdermal system 1079
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dyskinesia is associated with long-term treatment with
L-dopa, adjunctive therapy with L-dopa is eventually nee-
ded in almost all patients and it is unsurprising to find that
70 % (study SP516) and 80 % (study SP715) of patients
experienced dyskinesias in these long-term studies. It is of
note that these rates are significantly higher than in the
preceding double-blind trials (12 % for subjects random-
ized to rotigotine in CLEOPATRA-PD and 14 or 17 %
depending on rotigotine dose in PREFER). The high rates
seen here reflect the fact that all the patients had advanced
PD and were receiving L-dopa. In contrast, in a double-
blind, randomized trial comparing pramipexole and L-dopa
in patients with early PD, the incidence of dyskinesias was
10 % in the patients randomized to pramipexole (of whom
53 % required supplemental L-dopa), compared with 39 %
in those randomized to L-dopa alone (Parkinson Study
Group 2000).
While there was evidence for disease progression in
patients who participated in Studies SP715 and SP516,
mean UPDRS part II (ADL) scores remained improved
relative to double-blind baseline for approximately 2 and
2.5 years, respectively, and patients did not return to their
double-blind treatment baselines for their ‘‘ON’’-rated
UPDRS part III motor scores for up to 5 years. Thus,
motor function, as measured using the UPDRS part III,
remained improved relative to double-blind baseline for
the duration of both open-label extension studies. More-
over, there was no indication of any change in therapeutic
efficacy over time. It should be noted that the treating
physicians had the option of adding to the anti-PD med-
ication regimen used in the preceding CLEOPATRA-PD
and PREFER double-blind, placebo-controlled studies and
an average of 17 % of study participants were receiving
another dopaminergic agonist in addition to rotigotine.
Moreover, the dose of concomitant L-dopa was seen to
increase over time in both long-term studies. This com-
bination anti-PD treatment regimen may have contributed
to both the efficacy and AE outcomes in the two exten-
sion studies reported here.
It should also be noted that there is inconsistency in the
measurement of ‘‘OFF’’ time between the long-term studies
and their respective preceding double-blind studies (Poewe
et al. 2007; LeWitt et al. 2007) in which ‘‘OFF’’ time (in
each 30-min interval during a 24-h day) was recorded in a
patient diary. In the CLEOPATRA-PD study, the absolute
mean change in daily ‘‘OFF’’ time for the rotigotine group
between baseline and the end of the maintenance period
was -1.6 h compared with placebo (Poewe et al. 2007). In
the PREFER study, the absolute mean change in daily
‘‘OFF’’ time between baseline and the end of the mainte-
nance period was -2.7 h for the 8 mg/24 h rotigotine
group and -2.1 h for the 12 mg/24 h rotigotine group,
compared with -0.9 h for the placebo group (LeWitt et al.
2007). The measurement of ‘‘OFF’’ time using a patient
diary was impractical over the long period of the open-
label studies and was, therefore, measured using questions
in the UPDRS part IV. Although no comparisons can be
made, it is clear that even after up to 6 years of open-label
treatment, rotigotine treatment was associated with an
improvement in the daily proportion of time spent in the
‘‘OFF’’ state.
In summary, these open-label extension studies have
demonstrated the safety, tolerability and efficacy of the
rotigotine transdermal system, in combination with L-dopa,
for advanced PD patients followed for up to 6 years.
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